Get the Stockscreener App
1.58
1.25%
-0.02
After Hours:
1.57
-0.01
-0.63%
Adial Pharmaceuticals Inc stock is traded at $1.58, with a volume of 139.83K.
It is down -1.25% in the last 24 hours and down -9.71% over the past month.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
See More
Previous Close:
$1.60
Open:
$1.61
24h Volume:
139.83K
Relative Volume:
1.29
Market Cap:
$2.26M
Revenue:
-
Net Income/Loss:
$-7.98M
P/E Ratio:
-0.1802
EPS:
-8.7693
Net Cash Flow:
$-6.49M
1W Performance:
+1.94%
1M Performance:
-9.71%
6M Performance:
-80.67%
1Y Performance:
-90.87%
1-Day Range:
$1.56
$1.65
1-Week Range:
$1.51
$1.65
52-Week Range:
$1.51
$18.90
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
Name
Adial Pharmaceuticals Inc
Sector
Industry
Phone
434-422-9800
Address
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Compare ADIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
1.58 | 2.28M | 0 | -7.98M | -6.49M | -8.7693 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-18 | Initiated | Maxim Group | Buy |
| Oct-11-18 | Initiated | Dawson James | Buy |
Adial Pharmaceuticals Inc Stock (ADIL) Latest News
EBIT per share of Adial Pharmaceuticals, Inc – NASDAQ:ADIL - TradingView
ADIL Stock Price, Quote & Chart | ADIAL PHARMACEUTICALS INC (NASDAQ:ADIL) - ChartMill
Adial Pharmaceuticals files patent application for AD04 By Investing.com - Investing.com South Africa
Adial Pharmaceuticals files patent application for AD04 - Investing.com
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 - The Manila Times
Adial seeks U.S. patent that could protect its lead alcohol-use drug to 2045 - Stock Titan
Adial Pharmaceuticals Files New U.S. Utility Patent Application For AD04 Targeting Alcohol Use Disorder - marketscreener.com
Exclusive: Adial Pharmaceuticals clears manufacturing milestone ahead of pivotal study for alcohol use disorder drug - MSN
Why did Adial Pharmaceuticals stock plunge over 20% after hours today? - MSN
Peripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals (ADIL) Submits Application to FDA's National Priority Voucher Program - GuruFocus
Adial Pharmaceuticals applies for FDA priority voucher program - Investing.com
Adial Pharmaceuticals applies for FDA priority voucher program By Investing.com - Investing.com India
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program - The Manila Times
Adial Pharmaceuticals lead drug fits new policy mood as bipartisan bill signals broader lens on alcohol use disorder - MSN
Adial Pharmaceuticals (ADIL) price target decreased by 10.26% to 23.80 - MSN
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug - Sahm
Adial Pharmaceuticals completes AD04 demonstration batch production By Investing.com - Investing.com Australia
ADIL (Adial Pharmaceuticals Inc) reports wider than expected Q4 2025 loss, yet stock notches 2.53 percent gain today.Quick Ratio - UBND thành phố Hải Phòng
Adial Pharmaceuticals (ADIL) Advances Production for Phase 3 Cli - GuruFocus
Adial Pharmaceuticals completes AD04 demonstration batch production - Investing.com
Adial Pharmaceuticals Completes Successful AD04 Demonstration Batch Production - Intellectia AI
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Di - Benzinga
Adial Pharmaceuticals Successfully Completes Manufacturing Of Demonstration Batch Production Enabling Clinical And Registration Production For AD04 Planned Phase 3 Trial - marketscreener.com
Adial Pharma (ADIL) Stock: Technical Setup (Flirts with Breakout) 2026-04-18Professional Trade Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
Adial Pharmaceuticals regains compliance with Nasdaq stockholders’ equity listing requirement - MSN
ADIL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Published on: 2026-04-10 14:04:42 - baoquankhu1.vn
Adial Pharmaceuticals Files 8-K on Executive Changes and Restricted Stock Award Agreement - Minichart
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan - TipRanks
Adial Pharmaceuticals grants restricted stock awards to Cary Claiborne, Vinay Shah and Tony Goodman - TradingView
[Form 4] ADIAL PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Adial Pharmaceuticals (ADIL) director receives 9,185 stock options at $1.64 strike - Stock Titan
Adial (NASDAQ: ADIL) awards RSAs and stock options to board members - Stock Titan
Director at Adial (NASDAQ: ADIL) receives 9,185 restricted shares - Stock Titan
Adial Pharmaceuticals (ADIL) CFO receives 17,325-share restricted stock grant - Stock Titan
ADIAL (ADIL) director awarded 9,185 restricted shares in equity grant - Stock Titan
Adial Pharmaceuticals (NASDAQ: ADIL) CEO granted 37,985 shares - Stock Titan
Is Adial Pharma (ADIL) Stock Trending Down | Price at $1.79, Up 5.92%Community Volume Signals - Cổng thông tin điện tử tỉnh Lào Cai
Investor Mood: Will Adial Pharmaceuticals Inc benefit from government policy2026 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Is Adial Pharma (ADIL) Stock Overpriced Now | Price at $1.69, Down 2.31%Cycle Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Hedge Fund Bets: Whats the MACD signal for Adial Pharmaceuticals Inc2026 Dividend Review & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Adial Pharmaceuticals Inc Stock (ADIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):